Ultra-early in-cath lab evolocumab achieves rapid lipid target attainment and lipid quality improvement in acute coronary syndrome: a real-world propensity score-matched study

Why clinicians should know about it

• Picked for Cardiology and Cardiovascular Medicine (paper of the day, 7 August 2026).

Abstract

BACKGROUND: Current guidelines mandate stringent low-density lipoprotein cholesterol (LDL-C) control for patients with acute coronary syndrome (ACS). However, real-world evidence regarding the ultra-early, in-cath lab initiation of PCSK9 inhibitors and their impact on lipid quality-specifically the clearance of highly atherogenic small dense LDL (sdLDL)-remains scarce. This study aimed to evaluate the short-term efficacy and safety of this ultra-early evolocumab intervention strategy. METHODS: This real-world, prospective observational cohort study categorized ACS patients into three treatment groups: statin monotherapy, statin plus ezetimibe, and statin plus evolocumab. Evolocumab was administered ultra-early in the catheterization laboratory immediately after angiographic confirmation. A rigorous propensity score matching (PSM) was conducted to balance baseline characteristics. Primary endpoints included the 4-week LDL-C target achievement rate (<1.4 mmol/L and ≥50% reduction). Secondary endpoints focused on sdLDL clearance and safety outcomes. RESULTS: From an initial screening pool of 665 patients, a rigorous PSM established a final core analysis cohort of 382 matched patients (127 in the statin monotherapy group, 127 in the ezetimibe group, and 128 in the evolocumab group). At 4 weeks, the evolocumab group demonstrated a substantially higher dual LDL-C target attainment rate compared to the ezetimibe group (66.4% vs. 33.1%, Statin + Evolocumab vs. Statin + Ezetimibe; P < 0.001). Additionally, the statin plus ezetimibe group showed significant improvement over statin monotherapy (33.1% vs. 8.7%, Statin + Ezetimibe vs. Statin Monotherapy; P < 0.001). Furthermore, evolocumab exhibited a profound superiority in the clearance of pathogenic sdLDL particles, achieving a median reduction rate of 69.08% vs. 48.07% in the ezetimibe group (Statin + Evolocumab vs. Statin + Ezetimibe; P < 0.001). Safety profiles were comparable across all groups, with no significant differences in overall adverse events (P = 0.171). CONCLUSIONS: The ultra-early, in-cath lab initiation of evolocumab in ACS patients drives rapid, large-scale LDL-C target attainment and demonstrates an absolute advantage in the marked reduction of highly atherogenic sdLDL particles. This deep reversal of the lipid burden provides robust real-world evidence supporting the forward-shifting of intensive lipid-lowering interventions in the acute phase of ACS. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2600118799.

Abstract as published, via PubMed.